mallika Alvala

Dr. mallika Alvala

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2014 in Apoptosis
Verified
Journal Article
Closed access
PDF file
SSShweta Shrivastava
Shweta Shrivastava
PKPrasad Kulkarni
Prasad Kulkarni
DTDinesh Thummuri
Dinesh Thummuri
MJManish Kumar Jeengar
Manish Kumar Jeengar
VNVGM Naidu
VGM Naidu
SRSistla Ramakrishna
Sistla Ramakrishna

11 March 2020
Verified
Book Chapter
Open access
PDF file
ASAAFTAAB SETHI
AAFTAAB SETHI
KJKhusbhoo Joshi
Khusbhoo Joshi
KSK. Sasikala
K. Sasikala
MAmallika Alvala
mallika Alvala
The process of hunt of a lead molecule is a long and a tedious process and one is often demoralized by the endless possibilities one has to search through. Fortunately, computational tools have come to the rescue and have undoubtedly played a pivotal role in rationalizing the path to drug discovery. Of all techniques, molecular docking has played a crucial role in computer aided drug design and has swiftly gained ranks to secure a valuable position in the modern scenario of structure-based drug design. In this chapter, the principle, sampling algorithms, scoring functions and diverse available software’s for molecular docking have been summarized. We demonstrate the interplay of docking, classical techniques of structure-based design and X-ray crystallography in the process of drug discovery. In addition, we dwell upon some of the limitations faced in docking studies. Finally, several success stories of molecular docking approaches in drug discovery have been highlighted, concluding with remarks on molecular docking for the future.

12 December 2017 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
RNRamya Nuti
Ramya Nuti
SNsridhar goud nerella
sridhar goud nerella
ASA. Prasanth Saraswati
A. Prasanth Saraswati
RARavi Alvala
Ravi Alvala
MAmallika Alvala
mallika Alvala
Background: Antimicrobial resistance (AMR) has posed a serious threat to global public health and it requires immediate action, preferably long term. Current drug therapies have failed to curb this menace due to the ability of microbes to circumvent the mechanisms through which the drugs act. From the drug discovery point of view, the majority of drugs currently employed for antimicrobial therapy are small molecules. Recent trends reveal a surge in the use of peptides as drug candidates as they offer remarkable advantages over small molecules. Methods: Newer synthetic strategies like organometalic complexes, Peptide-polymer conjugates, solid phase, liquid phase and recombinant DNA technology encouraging the use of peptides as therapeutic agents with a host of chemical functions, and tailored for specific applications. In the last decade, many peptide based drugs have been successfully approved by the Food and Drug Administration (FDA). This success can be attributed to their high specificity, selectivity and efficacy, high penetrability into the tissues, less immunogenicity and less tissue accumulation. Considering the enormity of AMR, the use of Antimicrobial Peptides (AMPs) can be a viable alternative to current therapeutics strategies. AMPs are naturally abundant allowing synthetic chemists to develop semi-synthetics peptide molecules. AMPs have a broad spectrum of activity towards microbes and they possess the ability to bypass the resistance induction mechanisms of microbes. Result: The present review focuses on the potential applications of AMPs against various microbial disorders and their future prospects. Several resistance mechanisms and their strategies have also been discussed to highlight the importance in the current scenario. Conclusion: Breakthroughs in AMP designing, peptide synthesis and biotechnology have shown promise in tackling this challenge and has revived the interest of using AMPs as an important weapon in fighting AMR.

1 May 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SNSuresh Narva
Suresh Narva
SCSurendar Chitti
Surendar Chitti
BBBhaskara Rao Bala
Bhaskara Rao Bala
MAmallika Alvala
mallika Alvala
NJNishant Jain
Nishant Jain
KSKondapalli Venkata Gowri Chandra Sekhar
Kondapalli Venkata Gowri Chandra Sekhar

20 May 2021 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
ASAaftaab Sethi
Aaftaab Sethi
SSSwetha Sanam
Swetha Sanam
RARavi Alvala
Ravi Alvala
MAmallika Alvala
mallika Alvala
Galectins are ubiquitous in nature. They have established themselves as a protein family of high therapeutic potential and play a role in a wide variety of diseases like cancer, fibrosis, and Alzhe...

1 June 2019 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SNsridhar goud nerella
sridhar goud nerella
MSMohammed Ghouse Shaik
Mohammed Ghouse Shaik
Arifuddin MohammedArifuddin Mohammed
Arifuddin Mohammed
MAmallika Alvala
mallika Alvala
AAAndrea Angeli
Andrea Angeli
Claudiu SupuranClaudiu Supuran
Claudiu Supuran